Table 8 Univariate sensitivity analysis
Parameters | ICER per LY (€) | ICER per QALY (€) |
|---|---|---|
Palivizumab dosage scheme | ||
Total | 25,352.07 | 14,129.26 |
BPD | 12,532.56 | 7,902.66 |
< 33 weeks | 30,387.26 | 15,936.20 |
33–35 weeks | 40,857.49 | 21,476.58 |
Annual mean cost per patient with recurrent wheezing | ||
Total | 15,437.90 – 15,699.62 | 8,603.88 – 8,749.74 |
BPD | 4,225.56 – 4,438.94 | 2,664.51 – 2,799.06 |
< 33 weeks | 17,717.48 – 18,054.36 | 9,291.70 – 9,468.37 |
33–35 weeks | 28,248.76 – 28,585.65 | 14,848.85 – 15,025.93 |
Probability of developing recurrent wheezing within 24 months from enrollment | ||
Total | 15,857.51 | 8,837.74 |
BPD | 4,577.05 | 2,886.15 |
< 33 weeks | 18,253.99 | 9,573.06 |
33–35 weeks | 28,782.64 | 15,129.48 |